The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

The ability to exploit the immune system as a weapon against cancer has revolutionised the
treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs) …

Recently, clinical trials have demonstrated promising efficacy for novel HER2-targeted
therapies in HER2-low breast cancers, raising the prospect of including a HER2-low …

Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …

Objectives Recent clinical trials have demonstrated significant clinical benefits from novel
therapeutic compounds in breast cancer patient with human epidermal growth factor …

Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest
outcomes, and is associated with a high risk of relapse and metastasis. The treatment …

This comprehensive review delves into the rapidly evolving arena of cancer vaccines.
Initially, we examine the intricate constitution of the tumor microenvironment (TME), a …

Many immune suppressive mechanisms utilized by triple negative breast cancer (TNBC) are
regulated by oncogenic epithelial-to-mesenchymal transition (EMT). How TNBC EMT …

Simple Summary Breast cancer emergencies have become a rapidly evolving field in
medicine during the last ten years. Carcinogenesis is a multiparametric process that …

A novel and rapid therapeutic approach is the treatment of human breast cancer by
enhancing the host's immune system. In initial findings, program death one (PD-1) and …